Fig. 6: Halofuginone effect on TMPRSS2 requires intracellular lysines. | Nature Communications

Fig. 6: Halofuginone effect on TMPRSS2 requires intracellular lysines.

From: A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry

Fig. 6

A Immunoblot analysis of Beas-2B cells with control or DCAF1 siRNA treatment followed by halofuginone (HFG) treatment (6 h). TMPRSS2 densitometry represent mean ± SEM (n = 3 biologically independent samples). B TMPRSS2 intracellular lysines were assayed for their responsiveness to HFG through the HiBiT assay, data represent mean ± SEM (n = 3 biologically independent samples). C HiBiT-tagged TMPRSS2 WT and 4KR lysine mutant equivalently reached the plasma membrane. Data from extracellular HiBiT assay represent mean ± SEM (n = 5 biologically independent samples). D HFG treatment reduces WT but not mutant lysine TMPRSS2 protein from reaching cellular membrane. Data from extracellular HiBiT assay represent mean ± SEM (n = 5 biologically independent samples). P-values are shown for comparisons to control, or as indicated by one-way ANOVA with Dunnett’s test of multiple comparisons (A) or two-way unpaired t-test (B–D).

Back to article page